Quarterly report pursuant to Section 13 or 15(d)

Commitments And Contingencies (Details)

v3.10.0.1
Commitments And Contingencies (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 16, 2018
unit
$ / unit
Dec. 18, 2015
USD ($)
unit
Nov. 30, 2017
$ / unit
Sep. 30, 2018
USD ($)
extension
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2013
Oct. 31, 2017
Operating Leased Assets [Line Items]                  
Noncontrolling interest ownership percentage by Noncontrolling Owners                 10.00%
Rent expense         $ 44,000   $ 132,000    
Baltimore Office                  
Operating Leased Assets [Line Items]                  
Period of abatement               3 months  
Rent expense       $ 44,000   $ 132,000      
Rockville Office                  
Operating Leased Assets [Line Items]                  
Period of abatement       12 months          
Annual base rent       $ 161,671          
Annual rent increase (as a percent)       2.50%          
Lease term       10 years   10 years      
Number of optional extensions | extension       2          
Lease renewal term       5 years   5 years      
Termination fee       $ 308,889          
Karbinal Agreement | TRIS Pharma                  
Operating Leased Assets [Line Items]                  
Minimum quantity required | unit 70,000                
Make whole payment (in dollars per unit) | $ / unit 30                
Accrued make whole payment       $ 300,000   $ 300,000      
Zylera | Ulesfia Supply Agreement                  
Operating Leased Assets [Line Items]                  
Price (in dollars per unit) | $ / unit     58.84            
Management and handling fee (in dollars per unit) | $ / unit     3.66            
Management and handling fee annual price increase     10.00%            
Zylera | Ulesfia Supply Agreement | Lachlan Pharmaceuticals                  
Operating Leased Assets [Line Items]                  
Minimum quantity required | unit   20,000              
Long-term purchase commitment   $ 1,200,000              
Minimum royalty   $ 3,000,000              
Indemnification of post-acquisition losses, (as a percent)           50.00%